A responsive outcome for Parkinson's disease neuroprotection futility studies. - Test2 - elhamkhani - TriplyDB

A responsive outcome for Parkinson's disease neuroprotection futility studies.

A responsive outcome for Parkinson's disease neuroprotection futility studies.

http://www.wikidata.org/entity/Q39217591

about

Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results Caffeine and progression of Parkinson disease Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III.Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study Clinician versus machine: reliability and responsiveness of motor endpoints in Parkinson's disease Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience.A latent model approach to define event onset time in the presence of measurement error.Using 'dead or dependent' as an outcome measure in clinical trials in Parkinson's disease.The futility study--Progress over the last decade.Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?Predictors of time to initiation of symptomatic therapy in early Parkinson's disease.Protection against Parkinson's disease progression: clinical experience.Study in Parkinson disease of exercise (SPARX): translating high-intensity exercise from animals to humans Targets for neuroprotection in Parkinson's disease Designing clinical trials for dystonia.Milestones in movement disorders clinical trials: advances and landmark studies.The promise of futility trials in neurological diseases.Biomarkers in Parkinson's disease: a funder's perspective.Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues.Reply to Drs. Olanow and Rascol.Emtonjeni-A Structural Intervention to Integrate Sexual and Reproductive Health into Public Sector HIV Care in Cape Town, South Africa: Results of a Phase II Study.Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials.Longitudinal change of clinical and biological measures in early Parkinson's disease: Parkinson's progression markers initiative cohort.Quantifying Motor Impairment in Movement Disorders.

P2860

Q26995786-3F1DF5A3-E3B4-4BB7-BBFB-E03371443197 Q30407150-DD3827FD-37D0-4AC3-B48D-7A9E6FA7A0B7 Q30432945-0FA4BB1E-6779-42E2-A774-9A4F5D5D16A5 Q30494108-A6BD4779-1644-416E-93AE-3B63F61D652E Q30577157-1FF7EF18-ABFC-429A-8033-8458271863BA Q33639008-0D4A81F1-EB47-462F-9FB5-313A6DB0D297 Q33731897-070CAFFC-E7C8-4A33-B55E-DD1A9FA7FF62 Q34301396-3D72DA6F-53E4-4926-A4D3-1FD643351D3F Q34373748-2A4FE95E-59AA-4E22-ABD5-11A11F84CE5B Q35048310-6DECE846-F0D1-4A66-89B4-9847954EB34C Q36264697-302D22F2-F3A9-4B07-9A47-1D159FEE1EE5 Q36499640-0004900C-AA6D-486C-91F0-3A44AE5E669E Q37062111-A92AFA13-810D-4C22-8EB0-E1656F927B42 Q37131239-ADCF6F7E-318F-4873-96F9-9459A6604594 Q37161380-B439A04D-54CA-4EA0-9FB8-AE077BE99EEC Q37302453-16241844-2B8C-4DCF-A841-B15098C02202 Q37506514-CC1DBD44-1B79-4BE8-B3DF-9488A7BA2014 Q37882584-4B58B6FC-FF8D-4068-958E-B54C4956190E Q38380170-3453D9E8-FA78-4977-9E2E-201B7AB3BC31 Q39827858-05BB23D8-FD19-476A-88BC-A36DC4E28930 Q40027470-74EFC8C9-57B7-4508-8D5F-BF1FC861BCED Q40405786-88C5986D-F16D-4A72-BD0E-D00723A61AFC Q40494176-9251A045-9B13-4670-8855-B17E5F869E56 Q47352832-E0AB4B91-D738-4D7B-865C-534807EDA558 Q51759987-42CABE26-ECA2-4E51-A76C-878D9ABE954F Q55244629-8DC7EC33-08EA-4AF8-9894-EEA5611B56E5

P2860

A responsive outcome for Parkinson's disease neuroprotection futility studies.

http://www.wikidata.org/entity/Q39217591

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh

2005年學術文章

@zh-hant

name

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@en

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@nl

type

label

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@en

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@nl

prefLabel

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@en

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@nl

P1433

Q39217591-2E1DDB3F-188B-482C-B0A7-F615E093189A

P1476

Q39217591-7CD47C93-2F32-4990-8064-643C7EAD5BF5

P2093

Q39217591-08745FCF-6713-4489-AC0B-66B3719E99DA

Q39217591-65045C0F-5A8B-4BC2-9BDA-8C437F2791F7

Q39217591-715CD98F-BA46-4948-B14F-6CEE8C995B46

Q39217591-746E0591-F066-40D5-AA13-ABD425D9CF39

Q39217591-8787A6CA-5A7F-44C3-9844-50D50F85BE5B

Q39217591-8BEC6FA0-CA16-4143-A769-B44D354ED6CF

Q39217591-966F4DCA-48A1-48E4-B461-55A106BA04F5

Q39217591-AD9FD802-6B16-4547-A6B6-4671F402D38A

Q39217591-E592E066-0BE4-4E96-9F05-DA4D6D62C4C6

Q39217591-F54BB209-72D6-4BCD-B1DF-0C1D3D122A32

P2860

Q39217591-465E70A7-2D9A-444B-9D3F-CF3A57B70B5E

Q39217591-DB174C49-7F3B-40FF-A2CA-2A9B40470D2E

P304

Q39217591-7FB80EC2-87A2-42AE-9867-10443254B593

P31

Q39217591-7B72AFE0-112E-48F5-8DD0-1D2CCA8D8B1D

P356

Q39217591-64E8C30E-034A-4DF7-9CBE-B057CA30F9A9

P433

Q39217591-8B09B5F0-A333-478E-AA28-BEC38F77710F

P478

Q39217591-572FEFD0-D277-4668-9B6E-2790D128913B

P50

Q39217591-02DF4248-A381-4B88-8BC4-61C95157E537

Q39217591-1DFFEDBF-186E-42F7-983B-6D13BBC3AC7C

Q39217591-4438B9F4-38BE-41DD-9AA2-5C78CC5E1307

P577

Q39217591-C6479C9B-826D-425C-A845-FD40DF45AF99

P5875

Q39217591-84172942-8EE7-47DE-A749-7F100F227EB5

P698

Q39217591-5FB13ACC-170F-4D32-BDA1-AB2395C936C5

P921

Q39217591-FF935C71-2C7A-4FD7-A827-04859153C74C

P356

P1433

Annals of Neurology

P1476

A responsive outcome for Parkinson's disease neuroprotection futility studies.

@en

P2093

Barbara C Tilley

http://www.w3.org/2001/XMLSchema#string

Bernard Ravina

http://www.w3.org/2001/XMLSchema#string

Cornelia Kamp

http://www.w3.org/2001/XMLSchema#string

George Fredrick Wooten

http://www.w3.org/2001/XMLSchema#string

Jordan J Elm

http://www.w3.org/2001/XMLSchema#string

Kathleen Shannon

http://www.w3.org/2001/XMLSchema#string

NET-PD Investigators

http://www.w3.org/2001/XMLSchema#string

Paulo Guimaraes

http://www.w3.org/2001/XMLSchema#string

Peng Huang

http://www.w3.org/2001/XMLSchema#string

Yuko Y Palesch

http://www.w3.org/2001/XMLSchema#string

P2860

An Inventory for Measuring Depression

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment.

P304

197-203

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.20361

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Caroline M Tanner

Christopher G. Goetz

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8062695

http://www.w3.org/2001/XMLSchema#string

P698

15668964

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease